News headlines about Ophthotech Corp (NASDAQ:OPHT) have been trending somewhat negative this week, according to Alpha One Sentiment Analysis. The research firm, a division of Accern, identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ophthotech Corp earned a media sentiment score of -0.10 on Alpha One’s scale. Alpha One also assigned news stories about the biopharmaceutical company an impact score of 94 out of 100, indicating that recent press coverage is extremely likely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected AlphaOne’s rankings:
- ETFs with exposure to Ophthotech Corp. : April 19, 2017 (finance.yahoo.com)
- Checking the Overall Picture for Graphic Packaging Holding Company (GPK) (emfizz.com)
- How Ophthotech Corporation (OPHT) Delivered A Better ROE Than Its Industry? (simplywall.st)
- Ophthotech Corp (OPHT) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Ophthotech Corp (OPHT) Earning Somewhat Critical Media Coverage, Study Finds (americanbankingnews.com)
Separately, Zacks Investment Research cut Ophthotech Corp from a “buy” rating to a “hold” rating in a report on Monday, February 20th. Thirteen investment analysts have rated the stock with a hold rating, Ophthotech Corp has an average rating of “Hold” and a consensus target price of $53.70.
Ophthotech Corp (NASDAQ:OPHT) traded down 1.44% during midday trading on Friday, hitting $2.74. The stock had a trading volume of 490,269 shares. The stock’s market cap is $98.11 million. The firm has a 50 day moving average price of $3.39 and a 200 day moving average price of $15.74. Ophthotech Corp has a one year low of $2.71 and a one year high of $65.96.
In related news, CFO Glenn Sblendorio sold 7,388 shares of the company’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $3.56, for a total value of $26,301.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Somewhat Negative Press Coverage Extremely Likely to Impact Ophthotech Corp (OPHT) Share Price” was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.themarketsdaily.com/2017/04/21/somewhat-negative-press-coverage-extremely-likely-to-impact-ophthotech-corp-opht-share-price.html.
About Ophthotech Corp
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp and related companies with MarketBeat.com's FREE daily email newsletter.